Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Page 1
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.
Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, McGoon MD, Pasta DJ, Selej M, Burger CD, Frantz RP. Benza RL, et al. Among authors: mcgoon md. Chest. 2019 Aug;156(2):323-337. doi: 10.1016/j.chest.2019.02.004. Epub 2019 Feb 14. Chest. 2019. PMID: 30772387 Free article.
This analysis describes an update of the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk calculator (REVEAL 2.0) and compares it with recently published European Society of Cardiology/Respiratory Society guideline-derived risk assessment strat …
This analysis describes an update of the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk calculator (RE …
Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL.
Farber HW, Badesch DB, Benza RL, Elliott CG, Frantz RP, McGoon MD, Selej M, Zhao C, Frost AE. Farber HW, et al. Among authors: mcgoon md. J Heart Lung Transplant. 2018 Aug;37(8):948-955. doi: 10.1016/j.healun.2018.03.010. Epub 2018 Mar 17. J Heart Lung Transplant. 2018. PMID: 29653800
METHODS: Patients in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL), a 5-year observational study of Group 1 PAH, were categorized by presence or absence of supplemental oxygen use and by degree of DLCO reduction. ...
METHODS: Patients in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL), a 5-year observational study of Gr …
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.
Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL. Frantz RP, et al. Among authors: mcgoon md. Chest. 2018 Jul;154(1):126-135. doi: 10.1016/j.chest.2018.01.009. Epub 2018 Jan 31. Chest. 2018. PMID: 29355551 Free PMC article.
BACKGROUND: Plasma brain natriuretic peptide (BNP) level is a prognostic biomarker in pulmonary arterial hypertension (PAH). Its impact on long-term overall survival (OS) was investigated in the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertensio …
BACKGROUND: Plasma brain natriuretic peptide (BNP) level is a prognostic biomarker in pulmonary arterial hypertension (PAH). Its impact on l …
Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis.
Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW. Chakinala MM, et al. Among authors: mcgoon md. J Heart Lung Transplant. 2018 Jun;37(6):696-705. doi: 10.1016/j.healun.2017.10.028. Epub 2017 Nov 6. J Heart Lung Transplant. 2018. PMID: 29174533
In our analysis we assess the relationship between change in estimated glomerular filtration rate (eGFR) and outcomes in PAH patients in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL). METHODS: Overall 2,368 patients were classified into chron …
In our analysis we assess the relationship between change in estimated glomerular filtration rate (eGFR) and outcomes in PAH patients in the …
The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension.
Chen L, Larsen CM, Le RJ, Connolly HM, Pislaru SV, Murphy JG, McGoon MD, Frantz RP, Kane GC. Chen L, et al. Among authors: mcgoon md. Clin Respir J. 2018 Apr;12(4):1572-1580. doi: 10.1111/crj.12713. Epub 2017 Nov 8. Clin Respir J. 2018. PMID: 28905517

Severe TR was strongly predictive of greater 5-year mortality risk after adjustment for age, sex, functional class, 6-minute walk distance, diffusing capacity, RV size and pulmonary vascular resistance index (adjusted hazard ratio, 1.83; 95% CI, 1.38-2.41; P < .001). CONCLUSIO

…
Severe TR was strongly predictive of greater 5-year mortality risk after adjustment for age, sex, functional class, 6-minute walk distance, …
Five-Year outcomes of patients enrolled in the REVEAL Registry.
Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL. Farber HW, et al. Among authors: mcgoon md. Chest. 2015 Oct;148(4):1043-54. doi: 10.1378/chest.15-0300. Chest. 2015. PMID: 26066077 Free article. Clinical Trial.
The present study characterizes the 5-year survival in the United States of a new and previous diagnosis of PAH in patients stratified by baseline functional class (FC). The Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) is a 55-center ob …
The present study characterizes the 5-year survival in the United States of a new and previous diagnosis of PAH in patients stratified by ba …
Validation of two predictive models for survival in pulmonary arterial hypertension.
Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemarié JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD. Sitbon O, et al. Among authors: mcgoon md. Eur Respir J. 2015 Jul;46(1):152-64. doi: 10.1183/09031936.00004414. Epub 2015 Apr 2. Eur Respir J. 2015. PMID: 25837032 Free article.
The French Pulmonary Hypertension Network (FPHN) registry and the Registry to Evaluate Early And Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) have developed predictive models for survival in pulmonary arterial hypertension (PAH). ...
The French Pulmonary Hypertension Network (FPHN) registry and the Registry to Evaluate Early And Long-term Pulmonary Arterial Hyperte …
Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis.
Benza RL, Miller DP, Foreman AJ, Frost AE, Badesch DB, Benton WW, McGoon MD. Benza RL, et al. Among authors: mcgoon md. J Heart Lung Transplant. 2015 Mar;34(3):356-61. doi: 10.1016/j.healun.2014.09.016. Epub 2014 Sep 28. J Heart Lung Transplant. 2015. PMID: 25447572 Free article.
BACKGROUND: Data from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) were used previously to develop a risk score calculator to predict 1-year survival. ...
BACKGROUND: Data from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) were u …
Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance.
Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Farber HW, et al. Among authors: mcgoon md. J Heart Lung Transplant. 2015 Mar;34(3):362-8. doi: 10.1016/j.healun.2014.08.020. Epub 2014 Aug 28. J Heart Lung Transplant. 2015. PMID: 25312386 Free article.
METHODS: Patients in the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) with 6MWD at enrollment, with or without a follow-up assessment within the first year of observation, were included. ...
METHODS: Patients in the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) with 6M …
Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry.
Burger CD, Long PK, Shah MR, McGoon MD, Miller DP, Romero AJ, Benton WW, Safford RE. Burger CD, et al. Among authors: mcgoon md. Chest. 2014 Nov;146(5):1263-1273. doi: 10.1378/chest.14-0193. Chest. 2014. PMID: 24901386 Free PMC article. Clinical Trial.
BACKGROUND: Hospitalization is an important outcome in pulmonary arterial hypertension (PAH), shown previously to correlate with survival. Using the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry), we sought to characterize first-time hosp …
BACKGROUND: Hospitalization is an important outcome in pulmonary arterial hypertension (PAH), shown previously to correlate with survival. U …
52 results